Cencora, Inc. (NYSE:COR) Shares Sold by Andra AP fonden

Andra AP fonden trimmed its position in Cencora, Inc. (NYSE:COR) by 90.6% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,200 shares of the company’s stock after selling 97,800 shares during the period. Andra AP fonden’s holdings in Cencora were worth $2,292,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Swedbank AB boosted its stake in Cencora by 2.3% in the third quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock valued at $313,863,000 after acquiring an additional 31,104 shares during the period. Graypoint LLC boosted its stake in Cencora by 7.8% in the third quarter. Graypoint LLC now owns 1,171 shares of the company’s stock valued at $264,000 after acquiring an additional 85 shares during the period. Summit Global Investments acquired a new position in Cencora in the third quarter valued at approximately $297,000. Fiera Capital Corp boosted its stake in Cencora by 8.9% in the third quarter. Fiera Capital Corp now owns 20,493 shares of the company’s stock valued at $4,613,000 after acquiring an additional 1,672 shares during the period. Finally, CWA Asset Management Group LLC acquired a new position in Cencora in the third quarter valued at approximately $285,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of NYSE:COR opened at $254.54 on Monday. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The stock has a market cap of $49.36 billion, a price-to-earnings ratio of 36.21, a PEG ratio of 1.31 and a beta of 0.51. The stock’s 50 day moving average price is $244.34 and its 200 day moving average price is $238.39. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.86%. Cencora’s payout ratio is 31.29%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on COR. Mizuho began coverage on Cencora in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price for the company. Wells Fargo & Company lifted their price target on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a report on Wednesday, January 29th. Evercore ISI lifted their price target on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. StockNews.com cut Cencora from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. lifted their price target on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $277.90.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the completion of the transaction, the chief executive officer now owns 51,070 shares in the company, valued at approximately $13,022,850. This trade represents a 8.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,648 shares of company stock valued at $2,862,342 over the last quarter. Corporate insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.